

Special Issue

Current and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis

Message from the Guest Editor

Psoriasis is a chronic, systemic, immune-mediated disease associated with several comorbidities. Although its pathogenesis is complex and not yet fully understood, the interleukin (IL)-23/IL-17 axis is currently thought to be its main pathogenic pathway. The knowledge acquired over the last decade regarding psoriasis's pathogenesis has led to the development of new targeted therapeutic options including biologic agents and small molecules (both oral and topical) that enable clinicians to better manage psoriasis patients. Main targets include cytokines related to the IL-23/IL-17 axis and their intracellular signalling pathway (JAK-STAT, PDE4 and others); however, many other agents (topical, oral and parenteral drugs) with different targets are in the pipeline. This Special Issue aims to review recent and future therapy developments for the treatment of psoriasis.

Guest Editor

Prof. Dr. Tiago Torres

1. Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2. Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

Deadline for manuscript submissions

closed (31 December 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/174332

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).